Page 1: Executive Overview: Financial Pulse of the Business This page establishes the commercial baseline. Revenue (€8.63M), Gross Margin (€2.42M), and 446K units sold are analyzed alongside growth trends and seasonality. The margin bridge clearly shows COGS as the dominant profitability lever, while promotional impact remains measured. Urban pharmacies lead performance, and 89% of revenue comes from non-promoted sales, signaling strong core demand resilience. Page 2: Geographic & Pharmacy Benchmarking Performance by Location Sales distribution across European markets reveals revenue concentration in key countries, with identifiable performance gaps. Benchmarking pharmacies against regional averages isolates true outperformers versus scale-driven volume leaders, and execution efficiency metrics highlight which pharmacies convert revenue into stronger margins. The geographic view reveals expansion opportunities and underperforming pockets that require operational focus. Page 3: Product Performance & Profit Drivers : Mix & Margin Strategy Prescription and OTC dominate revenue contribution, but profitability varies significantly across categories. The high-volume vs high-margin matrix exposes positioning imbalances and optimization opportunities. Pack configuration analysis confirms tablets and liquids as key revenue drivers. Pricing diagnostics cost-to-price ratio and discount intensity provide clarity on how commercial decisions directly influence margin outcomes. Page 4: Product Lifecycle & Launch Intelligence: Portfolio Sustainability Legacy products currently generate the largest revenue share, while growth-stage products signal future upside. With a median time-to-peak of 61 months, commercialization cycles are deliberate rather than rapid. Launch efficiency metrics show over one-third of products peak quickly, yet half demonstrate slow ramp-up, highlighting refinement opportunities in launch execution and portfolio renewal strategy.

Skills & Tools Used:

Share this Project: